Blood in the urine, and the cancer behind it

Painless gross hematuria is bladder cancer until proven otherwise. That sentence is the whole opening move — visible blood without pain, often intermittent, easy for a patient to dismiss when it clears on its own. It does not get to be a urinary tract infection or a coincidence until the bladder has been looked at directly. Microscopic hematuria carries far lower risk but still earns a workup in the right patient.

The workup, every time

Gross hematuria gets two studies that answer two questions:

• CT urogram — images the upper tracts (kidneys and ureters) to catch an upper-tract urothelial cancer and to stage.
• Cystoscopy — looks directly at the bladder lining, the only reliable way to see a flat or small tumor. Urine cytology can flag high-grade disease, especially carcinoma in situ.

The pivot: muscle, or no muscle

Bladder cancer is really two diseases that share a name, divided by whether the tumor has invaded the detrusor muscle:

• Non-muscle-invasive (NMIBC) — Ta, T1, and carcinoma in situ. Confined to mucosa/submucosa; the bladder can be preserved.
• Muscle-invasive (MIBC) — T2 and beyond. A fundamentally more dangerous disease that threatens the bladder and life.

What everyone gets wrong

Judging a TURBT by how much tumor was removed rather than what the specimen contains. The single most important quality marker is whether detrusor muscle is present in the resection specimen — without muscle in the sample, the pathologist cannot tell you whether the cancer invaded it, and the entire treatment decision hangs on exactly that. No muscle means an incomplete stage and often a mandatory re-resection.

The TURBT is graded not by the size of the divot but by the presence of muscle in the jar. No detrusor, no stage.

Non-muscle-invasive disease: keep the bladder, watch it closely

Treatment starts with a complete TURBT, then risk- adapted intravesical therapy:

• A single immediate post-op intravesical chemo instillation (e.g. mitomycin) lowers recurrence for low-risk tumors.
• Intravesical BCG for high-risk disease (high- grade T1, CIS) — an induction course of 6 weekly instillations followed by maintenance for up to 3 years. BCG is live attenuated mycobacterium that drives a local immune response.
• Re-resect high-risk T1 at 4–6 weeks — understaging is common, and the re-TURBT both restages and removes residual disease.

BCG-unresponsive disease is a hard problem: the choices narrow to radical cystectomy or newer salvage options (e.g. pembrolizumab, intravesical gemcitabine/docetaxel).

Muscle-invasive disease: the bladder has to go

The standard of care for fit patients is a sequence:

1. Neoadjuvant cisplatin-based chemotherapy — givenbeforesurgery; it improves survival and is the part most often skipped to the patient’s detriment. Cisplatin eligibility hinges on renal function.
2. Radical cystectomy with pelvic lymph node dissection — in men, cystoprostatectomy; in women, anterior exenteration.
3. Urinary diversion — an ileal conduit (a stoma, robust and simple) or an orthotopic neobladder (a reservoir built from bowel, anastomosed to the urethra, allowing near-normal voiding in selected patients).

Bladder preservation — maximal TURBT plus chemoradiation (trimodal therapy) — is a real alternative for carefully selected patients who are unfit for or decline cystectomy.

When it has spread

Metastatic urothelial cancer has moved fast lately. The EV-302 trial established enfortumab vedotin plus pembrolizumab — an antibody-drug conjugate with immunotherapy — as a first-line standard that outperformed platinum chemotherapy, a genuine shift in a field that had stalled for decades.

If you remember one thing

Painless gross hematuria buys a cystoscopy and a CT urogram, full stop. Then the whole disease turns on one word from the pathologist — muscle. Its presence or absence in an invaded tumor is the difference between a bladder you treat and keep and a bladder that has to come out.